{"id":546,"date":"2026-11-10T23:03:11","date_gmt":"2026-11-10T23:03:11","guid":{"rendered":"https:\/\/yowao.xyz\/index.php\/2026\/11\/10\/fda-warns-of-vision-loss-risk-linked-to-popular-glp-1-drugs-like-wegovy-zepbound\/"},"modified":"2026-11-10T23:03:11","modified_gmt":"2026-11-10T23:03:11","slug":"fda-warns-of-vision-loss-risk-linked-to-popular-glp-1-drugs-like-wegovy-zepbound","status":"publish","type":"post","link":"https:\/\/yowao.xyz\/index.php\/2026\/11\/10\/fda-warns-of-vision-loss-risk-linked-to-popular-glp-1-drugs-like-wegovy-zepbound\/","title":{"rendered":"FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound"},"content":{"rendered":"<p>Title: FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound<\/p>\n<p>URL Source: https:\/\/www.cnbc.com\/2026\/11\/10\/fda-warning-vision-loss-glp1-wegovy-zepbound.html<\/p>\n<p>Published Time: 2026-11-10T07:52:40+0000<\/p>\n<p>Markdown Content:<\/p>\n<p>The U.S. Food and Drug Administration is requiring new safety warnings on all GLP-1 drugs after finding evidence of a potential increased risk of a rare eye condition, the agency said on Monday.<\/p>\n<p>The condition, which can cause sudden vision loss, known as nonarteritic anterior ischemic optic neuropathy (NAION), is rare, and a causal relationship has not been established.<\/p>\n<p>The FDA is requiring the makers of all GLP-1 medications to [add a warning](https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential) about the potential increased risk of NAION associated with use of these medications, it said.<\/p>\n<p>NAION is a condition that can result in sudden decreased vision, including permanent vision loss. It is caused by decreased blood flow to the front part of the \u200boptic nerve \u2014 the underlying cause is not completely understood, however.<\/p>\n<p>NAION cases have been reported for all currently marketed GLP-1 products, the FDA said.<\/p>\n<p>Ozempic and Wegovy maker [Novo Nordisk](https:\/\/www.cnbc.com\/quotes\/NVO\/) said it \u201ccontinues to believe the data do not establish a cause-and-effect relationship, and we remain confident in the benefit-risk profile of our GLP-1 medicines.\u201d<\/p>\n<p>CNBC has reached out to [Eli Lilly,](https:\/\/www.cnbc.com\/quotes\/LLY\/) the company behind Mounjaro, Zepbound and Foundayo, for comment.<\/p>\n<p>Diabetes itself is a [known risk factor](https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3087834\/) for NAION, complicating efforts to determine if cases among GLP-1 users are caused by the medications or by patients\u2019 underlying health conditions.<\/p>\n<p>The FDA decision follows a review of clinical trials, real-world patient data, and published studies.<\/p>\n<p>An analysis of 126 trials involving more than 134,000 patients found 6.4 cases of NAION per 100,000 patient-years among GLP-1 users, compared with 3.8 among patients receiving other treatments or placebos.<\/p>\n<p>The FDA said it identified 15 probable NAION events, 10 in patients treated with GLP-1s and five in patients receiving a placebo, and no cases were identified among patients receiving other non-GLP-1 glucose-lowering medications.<\/p>\n<h3>Read more pharma news<\/h3>\n<p>\u2022 [A pharma giant is moving past one patent cliff \u2014 but another is already looming](https:\/\/www.cnbc.com\/2026\/10\/30\/novartis-remibrutinib-multiple-sclerosis.html)<\/p>\n<p>\u2022 [Eli Lilly hikes sales outlook, as CEO says there\u2019s room for \u2018dramatic\u2019 obesity market expansion](https:\/\/www.cnbc.com\/2026\/10\/29\/eli-lilly-lly-earnings-q3-2026.html)<\/p>\n<p>\u2022 [Novo\u2019s new strategy hinges on something it can\u2019t manufacture: investor trust](https:\/\/www.cnbc.com\/2026\/09\/24\/novo-nordisk-ceo-rebuild-investor-trust-strategy-backlash.html)<\/p>\n<p>\u2022 [Cholesterol drug setback casts doubt over multibillion-dollar race](https:\/\/www.cnbc.com\/2026\/09\/08\/novartis-cholesterol-setback-drug-race-eli-lilly-amgen.html)<\/p>\n<p>\u2022 [Doctors call Moderna, Merck cancer vaccine data a major advancement \u2014 despite Wall Street reaction](https:\/\/www.cnbc.com\/2026\/10\/23\/moderna-merck-cancer-vaccine-data.html)<\/p>\n<p>\u2022 [AstraZeneca may buck a decade of pharma strategy to buy U.S. scale](https:\/\/www.cnbc.com\/2026\/08\/06\/astrazeneca-bristol-myers-merger-talks.html)<\/p>\n<p>\u2022 [Trump\u2019s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply](https:\/\/www.cnbc.com\/2026\/07\/22\/trump-generic-drug-tariffs-prices-explained.html)<\/p>\n<p>\u2022 [Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising](https:\/\/www.cnbc.com\/2026\/07\/21\/novo-nordisk-sues-eli-lilly-glp-1-ads.html)<\/p>\n<p>\u2022 [Novo Nordisk\u2019s head start on GLP-1 pills forces investors to rethink Eli Lilly\u2019s dominance](https:\/\/www.cnbc.com\/2026\/05\/04\/novo-nordisk-wegovy-pill-beating-eli-lilly-foundayo-early.html)<\/p>\n<p>\u2022 [Prices, pipelines and patent cliffs: Inside pharma\u2019s big reset](https:\/\/www.cnbc.com\/2026\/02\/13\/pharma-earnings-stock-novo-lilly-drug-prices-pipelines-take-aways.html)<\/p>\n<p>\u2022 [UK\u2019s biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies](https:\/\/www.cnbc.com\/2026\/04\/29\/astrazeneca-gsk-q1-earnings-stock-sales-profit-trump-mfn-pharma.html)<\/p>\n<p>Several observational studies also identified an increased risk, supporting the FDA\u2019s concerns.<\/p>\n<p>The agency\u2019s findings were more mixed when comparing the risk of developing NAION from the use of GLP-1 drugs versus other commonly prescribed diabetes drugs.<\/p>\n<p>Real-world patient data found a statistically significant increase in the risk of NAION among GLP-1 users compared with patients taking DPP-4 inhibitors, another class of diabetes medications, but not compared with those taking SGLT-2 inhibitors, per the FDA. SGLT-2 inhibitors are another class of medicines that includes Jardiance and Farxiga.<\/p>\n<p>However, observational studies consistently reported an increased risk of NAION in patients with type 2 diabetes mellitus who started a GLP-1 treatment compared to those who initiated DPP-4 inhibitors or SGLT-2 inhibitors, the FDA added.<\/p>\n<p>The FDA\u2019s class-wide labeling action is \u201clikely to attract attention but should have limited impact on GLP-1 uptake,\u201d according to Citi analysts.<\/p>\n<p>It may temporarily increase patient and investor concern, but the rarity of NAION and substantial weight, glycemic, cardiovascular, renal, and sleep apnea benefits should preserve a favorable benefit-risk profile and limit changes to prescribing the medicines, they added.<\/p>\n<h3>[](https:\/\/www.cnbc.com\/2026\/11\/10\/fda-warning-vision-loss-glp1-wegovy-zepbound.html)Benefits versus risks<\/h3>\n<p>While GLP-1 drugs have been shown to lead to benefits beyond weight loss and controlling blood sugar levels, many also carry the FDA\u2019s strongest safety warning, known as a boxed warning, over a potential risk of thyroid tumors.<\/p>\n<p>Studies have shown that semaglutide, the active ingredient in Wegovy and Ozempic, and tirzepatide, the active ingredient in Mounjaro, cause thyroid C-cell tumors in rodents. It remains unknown whether the drugs cause these tumors, including a rare form of thyroid cancer, in humans.<\/p>\n<p>Both semaglutide and tirzepatide also carry warnings about diabetic retinopathy, another eye condition that can lead to blurred vision, difficulty seeing in low light, and, eventually, sight loss. Diabetic retinopathy is when high blood sugar damages the tiny blood vessels in the retina, the light-sensitive tissue at the back of the eye.<\/p>\n<p>In a two-year trial involving patients with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3% of patients treated with Ozempic, compared with 1.8% of those receiving a placebo, according to the drug\u2019s prescribing information.<\/p>\n<p>Mounjaro\u2019s FDA label separately warns that rapid improvements in blood sugar control have been associated with temporary worsening of diabetic retinopathy and recommends monitoring patients with a history of the condition.<\/p>\n<h3>[](https:\/\/www.cnbc.com\/2026\/11\/10\/fda-warning-vision-loss-glp1-wegovy-zepbound.html)FDA decision follows European warnings<\/h3>\n<p>European regulators flagged a risk of NAION associated with semaglutide [in June 2025.](https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy)<\/p>\n<p>The European Medicines Agency\u2019s safety committee concluded that NAION was a very rare side effect of semaglutide that may affect up to 1 in 10,000 people taking it, and recommended updating the drug\u2019s product information. The U.K.\u2019s medicines regulator followed with a [similar warning in February.](https:\/\/www.gov.uk\/drug-safety-update\/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion)<\/p>\n<p>Unlike the FDA\u2019s latest action, which covers all GLP-1 medications, the European and British warnings focused specifically on semaglutide.<\/p>\n<p>![Image 1: How GLP-1s are helping the hair care industry](https:\/\/image.cnbcfm.com\/api\/v1\/image\/108300235-1777574721281-gettyimages-2193045858-dscf7269.jpeg?v=1777574753&amp;w=750&amp;h=422&amp;vtcrop=y)<\/p>\n<p>watch now<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Title: FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound URL Source: https:\/\/www.cnbc.com\/2026\/11\/10\/fda-warning-vision-loss-glp1-wegovy-zepbound.html Published Time: 2026-11-10T07:52:40+0000 Markdown&hellip;<\/p>\n","protected":false},"author":1,"featured_media":547,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[117,118],"class_list":["post-546","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-business","tag-markets"],"_links":{"self":[{"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/posts\/546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/comments?post=546"}],"version-history":[{"count":0,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/posts\/546\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/media\/547"}],"wp:attachment":[{"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/media?parent=546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/categories?post=546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/yowao.xyz\/index.php\/wp-json\/wp\/v2\/tags?post=546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}